Barclays’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Barclays’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-27,000	Closed	-$3.56M	–	5661
2025 Q1	$3.56M	Hold	27,000	–	–	﹤0.01%	2184
2024 Q4	$2.26M	Buy	+27,000	New	+$2.22M	﹤0.01%	2790
2020 Q3	–	Sell	-3,700	Closed	-$95K	–	5663
2020 Q2	$95K	Buy	+3,700	New	+$74.9K	﹤0.01%	4557
2019 Q3	–	Sell	-32,900	Closed	-$427K	–	7210
2019 Q2	$427K	Buy	+32,900	New	+$422K	﹤0.01%	4466
2019 Q1	–	Sell	-6,500	Closed	-$74K	–	7392
2018 Q4	$74K	Buy	+6,500	New	+$105K	﹤0.01%	5247
2018 Q1	–	Sell	-2,000	Closed	-$29K	–	7399
2017 Q4	$29K	Buy	+2,000	New	+$30.9K	﹤0.01%	6102
2016 Q4	–	Sell	-180,000	Closed	-$2.74M	–	6879
2016 Q3	$2.74M	Buy	+180,000	New	+$7.28M	﹤0.01%	1736
2015 Q4	–	Sell	-185,700	Closed	-$7.43M	–	6679
2015 Q3	$7.43M	Buy	+185,700	New	+$6.06M	0.01%	1111

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Barclays's ITCI Position: Q2 2025 in Review

Barclays sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 49,003 shares — an estimated $6.46M sold.

Barclays first reported a position in ITCI in Q1 2014 and held it in 44 quarters. The position peaked at $14.9M in Q4 2023. 3 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

Barclays reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
Barclays sold 49,003 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $6.46M.
Barclays first reported a position in Intra-Cellular Therapies Inc. in Q1 2014 and held it in 44 quarters.
Barclays's Intra-Cellular Therapies Inc. position peaked at $14.9M in Q4 2023.
3 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Barclays's 13F filing for Q2 2025, filed 13 Aug 2025.